We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Breath Test Identifies Heart Failure in Patients

By LabMedica International staff writers
Posted on 11 Apr 2013
Acute decompensated heart failure (ADHF) is the most common indication for hospital admission, particularly in the elderly where using conventional clinical methods is unreliable.

The identification of those with impending decompensation frequently leaves insufficient lag time for therapeutic interventions, but by analyzing single puff of exhaled air from patients, it is possible to quickly determine whether they have heart failure.

Scientists at the Cleveland Clinic (Cleveland, OH, USA), collaborating with others, conducted a prospective, single-center cohort study to assess the feasibility of exhaled breath analysis to identify patients admitted for ADHF. More...
Of the 61 patients involved in the study, 25 had been hospitalized with heart failure as a primary diagnosis, 16 were healthy controls, and another 36 people were added to validate the positive research findings.

All breath analyses were performed within two hours of collection using selected ion flow tube mass spectrometry instrument (VOICE200 SIFT-MS, Syft Technologies; Christchurch, New Zealand). The investigators were able to correctly diagnose heart failure in all the patients who had been hospitalized with the disease. The breath test not only identified all the patients with heart failure, but also clearly distinguished them from cardiac cases without heart failure. The exhaled breath of patients with heart failure had considerably higher levels of organic compounds acetone and pentane, compared to those without heart failure.

Raed Dweik, MD, a pulmonologist and lead-investigator, in the Respiratory Institute at Cleveland Clinic, said, "While additional examination is needed to determine the true potential of breath analysis for heart failure identification in our patients, we're very encouraged by these results. The ability to identify patients with heart failure using a breath test has the potential for broad application due to its noninvasive nature and ease of application.” The authors concluded that future studies in exhaled breath metabolomics are needed to accelerate progress in the field of cardiovascular medicine. The study was published on April 2, 2013, in the Journal of the American College of Cardiology.

Related Links:

Cleveland Clinic
Syft Technologies




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Hematology Consumables
Bioblood Devices
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.